Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 28;15:8365–8380. doi: 10.2147/IJGM.S393270

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Shen et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

MALAT1 silencing increases the radiosensitivity of HCT116 cells. (A) MALAT1 silencing can increase the radiosensitivity of HCT116 cells. (B) Colony survival fraction at dose (0, 2, 4, 6 and 8 Gy) dependent manner compared to NC group. (C) GSEA of colorectal cancer expression profile in TCGA showed that G2M_CHECKPOINT was upregulated. (D) Activation or inhibition of G2M_CHECKPOINT pathway in 33 cancers. (E) Correlation analysis of MALAT1 expression level and G2M_CHECKPOINT in colorectal cancer. (F&G) MALAT1 silencing combined with radiation results in more HCT116 cells entering G2/M-phase arrest at 12 h (***p<0.005).